Myosin Ia inhibitors belong to a class of chemical compounds that have garnered attention in the field of cell biology and molecular motor protein research. These inhibitors are designed to specifically target and modulate the activity of Myosin Ia, a motor protein belonging to the myosin superfamily. Myosin Ia is widely distributed in various cell types and plays a pivotal role in intracellular transport, organelle movement, and cell membrane dynamics. It functions as an actin-based motor protein, utilizing the energy found in ATP hydrolysis to generate mechanical forces that drive cellular processes like vesicle trafficking, membrane tension regulation, and cell motility.
Myosin Ia inhibitors exert their effects by interfering with the motor activity of Myosin Ia, disrupting its ability to bind actin filaments and generate force. This interference can lead to alterations in intracellular transport, vesicle trafficking, and other cellular activities that rely on Myosin Ia-mediated movements. Researchers employ Myosin Ia inhibitors as valuable tools to investigate the specific roles of Myosin Ia in various cellular contexts and gain insights into the molecular mechanisms underlying intracellular transport and membrane dynamics. While the specific applications and broader implications of Myosin Ia inhibitors are subjects of ongoing research, their utility in unraveling the complexities of molecular motor proteins and their role in cellular processes is of paramount importance in the field of cell biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with the translocation step on the ribosome, potentially reducing Myosin Ia levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase, potentially decreasing Myosin Ia mRNA synthesis and protein expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Specifically inhibits RNA polymerase II, potentially reducing Myosin Ia mRNA transcription and subsequent protein expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling, which can lead to broad effects on protein synthesis, potentially affecting Myosin Ia expression. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Causes premature chain termination during protein synthesis, potentially resulting in decreased Myosin Ia levels. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Inhibits bacterial protein synthesis but can also affect mitochondrial protein synthesis, potentially influencing Myosin Ia expression. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Inhibits bacterial RNA polymerase but can also impact mitochondrial RNA polymerase, possibly affecting Myosin Ia protein levels. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Blocks N-linked glycosylation, which can lead to ER stress and potentially influence Myosin Ia expression. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Inhibits protein transport from the ER to the Golgi apparatus, potentially affecting Myosin Ia protein processing and expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can increase cellular protein levels but may affect Myosin Ia expression through feedback mechanisms. | ||||||